Abstract
The publication deals with the long and complicated history of pharmacotherapy of obesity, when many once successful drugs are no longer used for serious risks. Currently used and safe antiobesity drugs are discussed in detail, including the anorectics phentermine and the naltrexone / bupropion combination, as well as the intestinal lipase blocker orlistat and a very expanding group of incretin analogues used in obesity - so far liraglutide and semaglutide.
The book also discusses the treatment of obese type 2 diabetics with gliflosin and incretin analogues, as well as the pharmacotherapy of obesity in prediabetics and type 1 diabetics. A short chapter is devoted to the treatment of obesity in type 2 diabetics on insulin.
A separate chapter specifies how to specifically choose antiobesity drugs in practice. The final chapter outlines the perspectives of obesity pharmacotherapy and had to be updated repeatedly before publication.
Information on drugs being developed changes weekly, indicating that obesity pharmacotherapy is perhaps the most dynamically evolving field of pharmacotherapy.